Prostate Cancer Metastasis—Diagnosis and Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 12 December 2025 | Viewed by 246
Special Issue Editor
Special Issue Information
Dear Colleagues,
The aim of this Special Issue is to share the latest developments in the detection of metastasis in advanced prostate cancer. This may be an early event after primary curative treatment, the early detection of hormone-sensitive metastatic disease—whether it is oligometastatic or extensively metastatic—or the various stages of castration-resistant prostate cancer. There may be exclusive treatment options for non-metastatic CRPC and CRPC after one or several previous lines of treatment. Recent developments also include biomarker-based treatment, which predicts the applicability and prognosis of certain treatments. Last but not least, the recent addition of novel hormone treatments, chemotherapy, PSMA ligands, and genetic-based treatment modalities has led to the question of optimal sequences. In this Special Issue, original research articles and reviews are welcome.
We look forward to receiving your contributions.
Prof. Dr. Arnulf Stenzl
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- metastasis
- hormone-sensitive
- castration-resistant prostate cancer
- imaging
- PSMA
- ligand therapy
- sequence
- oligometastatic
- biomarker
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
